Lir Life Sciences Advances Needle-Free Obesity Treatment with Novel Transdermal GLP/GIP Delivery Platform
Key Insights
Lir Life Sciences (search) has completed the design of a comparative animal study to evaluate transdermal delivery of GLP/GIP (search)-based obesity (search) therapies using cell-penetrating peptide formulations.
The study will compare the effectiveness of transdermal delivery against standard subcutaneous injections by measuring blood glucose control following oral glucose challenges.
The research aims to identify the most suitable drug candidates for needle-free delivery and inform future Investigational New Drug (IND)-enabling studies.
Lir Life Sciences (search) Corp. has completed the design of a comparative animal study investigating cell-penetrating peptide-mediated delivery of GLP/GIP (search)-based obesity (search) therapies through its novel transdermal platform. The Vancouver-based company announced on December 10, 2025, that this research initiative represents a significant advancement in developing patient-friendly, needle-free delivery options for incretin therapies.
Novel Transdermal Platform for Obesity Treatment
The company's transdermal system utilizes cell-penetrating peptide (CPP) formulations to deliver GLP-1 (search) and GIP (search) hormones through the skin, potentially eliminating the need for subcutaneous injections. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are gut hormones called incretins that work by stimulating the pancreas to release insulin and help lower blood sugar levels. These hormones act through complementary biological pathways that can potentially improve glucose metabolism, energy balance, and weight regulation by targeting both metabolic and appetite-related mechanisms.
Study Design and Methodology
The controlled animal study will evaluate three clinically validated incretin therapies within the same delivery framework. Study subjects will be pre-treated with transdermal formulations of each drug, followed by an oral glucose challenge. The research team will assess delivery effectiveness by measuring blood glucose levels following glucose intake, comparing the efficiency of transdermal delivery with standard subcutaneous injections.
"By evaluating three of the most clinically validated incretin therapies within the same delivery framework, we are generating the comparative data needed to prioritize the strongest candidates for transdermal advancement," said Edward Mills, CEO of Lir Life Sciences (search). "Our aim with this study is to obtain clear insight into how these molecules behave with our CPP-enabled system and to inform our IND strategy."
Clinical Development Strategy
The comparative work is designed to map the performance envelope of Lir's CPP-enhanced transdermal platform across multiple GLP/GIP (search)-based therapies. The results are intended to help identify drug candidates that may align most effectively with the platform's capabilities, guiding the next stages of formulation optimization and clinical planning. This research will inform future research and development priorities, including which molecules are best suited for needle-free delivery and subsequent Investigational New Drug (IND)-enabling studies.
Addressing Treatment Barriers
Lir Life Sciences (search) believes that transdermal systems have the potential to improve comfort, accessibility, and long-term treatment adherence for individuals managing chronic metabolic conditions and evidence-based weight-loss treatments. The company is focused on researching and developing scalable and affordable treatments for obesity (search) using novel drug delivery methods, with the goal of improving access, adherence, and cost-efficiency in both developed and emerging markets.
The company's broader research and development roadmap endeavors to create safe, effective, and patient-friendly alternatives to injectable GLP/GIP (search)-based therapies. Lir Life Sciences (search) aims to address the global burden of obesity (search) with practical solutions based on established compounds and proven science, advancing transdermal patches and other novel delivery systems that mimic GLP-1 (search)'s natural appetite and blood sugar regulation functions.